Clinical Data New data build case for Roche’s oral BTK drug for MS PharmaphorumRoche remains confident in the prospects for its soon-to-be-filed oral BTK drug fenebrutinib for multiple sclerosis, despite safety concerns.Clinical DataNeuroscienceRead full story pharminent April 22, 2026 (Last updated: April 22, 2026) Pharmaphorum Roche remains confident in the prospects for its soon-to-be-filed oral BTK drug fenebrutinib for multiple sclerosis, despite safety concerns. Clinical DataNeuroscienceRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Pivotal trial of Moderna’s H5N1 bird flu jab gets underwayNext: MSD-backed Ray locks in $125m to back eye drug pipeline Related Stories Clinical Data Boehringer advances duo for aggressive cancers into phase 3 pharminent June 22, 2026 Clinical Data Edgewise slides as cardiomyopathy challenger to BMS, Cytokinetics falls short pharminent June 17, 2026 Clinical Data EHA26: BMS touts positive multiple myeloma data for two pipeline candidates pharminent June 17, 2026
